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Investigator led trials, whether of novel pharmaceutical
agents, surgery or complex non-drug therapies, face a
particular set of challenges. This is a selective review,
based on personal observations and experiences of trials
in my own field of stroke and clinical neuroscience over
the past 32 years.
The guiding principles of clinical trials – all too often
lost in the process of designing and managing clinical
trials - are: trials should address a ‘burning question’;t o
provide sufficiently reliable evidence to answer that
burning question (i.e. sufficient to change practice),
trials need to be large; to achieve large sample sizes,
trials need to be affordable and efficient in design and
conduct; and, investigatorsn e e dr i g o r o u s l yt oa p p l yt h e
principles of the ‘business model’ of clinical trials to
help overcome the many obstacles that inhibit trials.
From the 1980’s and into the early 2000’s, a series of
very successful large-scale investigator- led trials in car-
diovascular medicine and neuroscience had a substantial
impact on clinical practice worldwide: the ISIS 1,2,3 & 4
trials in acute myocardial infarction, IST and CAST in
acute stroke, CRASH in traumatic brain injury, ISAT in
the management of ruptured intracranial aneurysms. All
of these trials were conducted on remarkably modest
budgets by today’s standards. After 2004, the regulatory
environment changed significantly – especially for trials
in the UK – with the implementation of the EU direc-
tive on clinical trials, the changes to UK ethical
approvals system, and the introduction of the research
governance framework. These changes have undoubt-
edly substantially raised the costs of, and delayed imple-
mentation of, clinical trials (and I would argue those
costs and delays have disproportionately increased for
investigator-led trials).
There is little disagreement that trials like those listed
a b o v es i m p l yc o u l dn o tb eu n d e r t a k e ni nt h ec u r r e n t
regulatory environment. Clinical trials in the 21
st cen-
tury must therefore adapt to the new environment (or
die). However, for investigators planning their own trials
now, there are grounds for a degree of optimism, since
in the UK at least, several changes are underway that
reduce the risk that investigator trials might become
extinct. To name a few of these changes: the regulatory
environment will ease a little; the number of registered
clinical trials units in the UK has substantially increased
to support new investigators, and the NIHR/MRC fund-
ing models are adapting to meet the needs of clinical
trials; and, other changes are underway internationally
that may also facilitate investigator-led trials.
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